Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim
Summary
The Federal Trade Commission and multiple states have filed a contempt claim against Martin Shkreli. Authorities allege he broke a lifetime ban that was previously imposed following a trial regarding an illegal monopoly scheme for the medication Daraprim.
Shkreli was banned from the pharmaceutical industry after a trial found that he organized an illegal scheme to perpetuate a monopoly for the drug Daraprim.
Source: Read the full story at US Top News and Analysis
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.